Atopic dermatitis updates in 2026 included long-term upadacitinib safety, phase 3 amlitelimab and rademikibart data, and 5-year interim dupilumab results in children. A market report also listed multiple emerging therapies in late-stage development.
New data from 1,868 SEER-linked patients showed DecisionDx-Melanoma identified significant five-year survival differences within the same AJCC stage. The findings were presented at the 2026 AAD Annual Meeting.
Priovant Therapeutics' brepocitinib demonstrated significant efficacy in the Phase 3 VALOR trial for dermatomyositis, meeting its primary endpoint with a 15.3-point greater improvement in Total Improvement Score versus placebo at Week 52. The treatment showed meaningful corticosteroid tapering and improvements across all nine key secondary endpoints, with benefits sustained through one year. Additional analyses revealed rapid itch reduction and improved skin-related quality of life in patients.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05084417 |
A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions |
ENROLLING_BY_INVITATION |
